{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:51:33Z","timestamp":1792173093860,"version":"4.4.0"},"reference-count":14,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2020,2,1]]},"DOI":"10.1001\/jamacardio.2019.4665","type":"journal-article","created":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T11:36:05Z","timestamp":1576064165000},"page":"202","source":"Crossref","is-referenced-by-count":78,"title":["Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure"],"prefix":"10.1001","volume":"5","author":[{"given":"Adam D.","family":"DeVore","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute, Department of Medicine, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Morrow","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol I.","family":"Duffy","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Ambrosy","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, California"},{"name":"Division of Research, Kaiser Permanente Northern California, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrishikesh","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Department of Medicine, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"McCague","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Rocha","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Velazquez","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the PIONEER-HF Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"hbr190019r1","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"hbr190019r2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ahj.2018.01.004","article-title":"Rationale and design of the comparison of sacubitril\/valsartan versus enalapril on effect on NT-pro-BNP in patients stabilized from an acute heart failure episode (PIONEER-HF) trial.","volume":"198","author":"Velazquez","year":"2018","journal-title":"Am Heart J"},{"issue":"6","key":"hbr190019r3","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure.","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"hbr190019r4","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1161\/CIRCULATIONAHA.118.039331","article-title":"Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril\/valsartan or enalapril in the PIONEER-HF Trial.","volume":"139","author":"Morrow","year":"2019","journal-title":"Circulation"},{"issue":"22","key":"hbr190019r5","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.jacc.2016.09.931","article-title":"Prognostic Implications of changes in n-terminal pro-B-type natriuretic peptide in patients with heart failure.","volume":"68","author":"Zile","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"hbr190019r6","first-page":"A15567","article-title":"Short-term effect on cardiac biomarkers of initiation of sacubitril\/valsartan in hospitalized patients with heart failure and reduced ejection fraction: results of the transition study.","volume":"138","author":"Pascual-Figal","year":"2018","journal-title":"Circulation"},{"key":"hbr190019r7","article-title":"Association of change in n-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction [published online September 2, 2019].","author":"Januzzi","journal-title":"JAMA"},{"key":"hbr190019r8","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial [published online September 2, 2019].","author":"Desai","journal-title":"JAMA"},{"issue":"9","key":"hbr190019r9","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","article-title":"Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).","volume":"15","author":"McMurray","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"hbr190019r10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"hbr190019r11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"issue":"9","key":"hbr190019r12","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.jacc.2003.12.040","article-title":"Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial.","volume":"43","author":"Gattis","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hbr190019r13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2018.06.011","article-title":"Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization.","volume":"7","author":"Bhagat","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"16","key":"hbr190019r14","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines.","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2756356\/jamacardiology_devore_2019_br_190019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T14:48:22Z","timestamp":1582123702000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2756356"}},"subtitle":["Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial"],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2019.4665","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,1]]}}}